Introduction
An important therapeutic innovation with the potential to dramatically inhibit progression of the motor deficit in Parkinson's disease is the delivery of potent neurotrophic factors directly into the degenerated region of the brain. Delivery of a gene therapy vector or therapeutic agent into the brain via direct injection offers an effective method for bypassing the blood brain barrier and targeting a specific anatomical site. However, the large size and complex architecture of the human brain often prevents scalable translation of small animal experimental methods involving direct brain delivery into effective medical procedures. Previous clinical studies investigating the direct delivery of recombinant glial-derived neurotrophic factor (GDNF) protein into the putamen did not yield significant efficacy (Patel and Gill, 2007) . The reason for this disappointing outcome is still unclear, but sub-optimal distribution of infused GDNF protein is suspected. The generation of anti-GDNF antibodies in some subjects, along with reported cerebellar toxicity in Rhesus macaques after cessation of prolonged putamen infusion of GDNF, diminished enthusiasm for this approach (Hovland et al., 2007; Lang et al., 2006) . In contrast, gene therapy has become a more favored approach primarily because targeting of much lower levels of growth factor only to the nigrostriatal neurons seems to provide a way of harnessing the potency of neurotrophic factors while limiting the potential side effects that might be triggered through inadvertent escape of the neurotrophic factor into other parts of the brain or into peripheral circulation. Adenoassociated viral (AAV) vectors have emerged as the current vehicle 
